osteoarthritis
-
New funding fuels device-maker’s pursuit of FDA approval
Moximed snagged $40 million as it works to secure approval for its device, an implantable shock absorber for the knee designed to put off the need for full joint replacement. CEO Anton Clifford touts that the MISHA Knee System is the first of its kind.
-
Gilead, Galapagos sign $5.05B drug-development deal
The collaboration includes six drugs in development and more than 20 in preclinical development. It also amends an existing four-year-old partnership the two companies had regarding the autoimmune disease drug filgotinib.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Centrexion’s $67M Series D round to fund Phase 3 pain studies
Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.
-
Arthro Therapeutics raises $2.2M to support digital arthritis care
The company will use most of the new funding to build up its sales, business development and marketing operations, with the goal of fully entering the U.S. market by the second quarter of 2017.
-
Health IT, Hospitals, Startups
Can a healthcare app globalize one country’s fight against osteoarthritis?
Swedish startup Jojnts has developed a digital version of a national program to help people […]
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
